Development of therapeutic combinations targeting major cancer signaling pathways

Journal of Clinical Oncology

Volumn 31, Issue 12, 2013, Pages 1592-1605

  Yap, Timothy A ^a   Omlin, Aurelius ^a   De Bono, Johann S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANASTROZOLE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CRIZOTINIB; DABRAFENIB; DOCETAXEL; ERLOTINIB; EVEROLIMUS; EXEMESTANE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE; ONARTUZUMAB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; R 1507; RAF PROTEIN; RAS PROTEIN; SELUMETINIB; TAMOXIFEN; TIVANTINIB; TRAMETINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VEMURAFENIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; COUGHING; DIARRHEA; DIFFUSION WEIGHTED IMAGING; DOSE CALCULATION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG FEVER; DRUG RESEARCH; DRUG TARGETING; DRUG WITHDRAWAL; ECHOGRAPHY; ENDOMETRIUM CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; FRACTURE; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL STROMAL TUMOR; HEART LEFT VENTRICLE EJECTION FRACTION; HOT FLUSH; HUMAN; LOSS OF FUNCTION MUTATION; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CARCINOMA; STOMATITIS; TOXICITY TESTING; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84876541026     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.6418     Document Type: Article

References (72)

1. Macconaill LE, Garraway LA: Clinical implications of the cancer genome. J Clin Oncol 28: 5219-5228, 2010
2. Chin L, Andersen JN, Futreal PA: Cancer genomics: From discovery science to personalized medicine. Nat Med 17:297-303, 2011
3. Vivanco I, Mellinghoff IK: Epidermal growth factor receptor inhibitors in oncology. Curr Opin Oncol 22:573-578, 2010
4. Baselga J, Swain SM: Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463-475, 2009
5. Chiarle R, Voena C, Ambrogio C, et al: The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8:11-23, 2008
6. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002 (Pubitemid 34879334)
7. Sawyers CL, Hochhaus A, Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 99:3530-3539, 2002 (Pubitemid 34534519)
8. Turner N, Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer 10:116-129, 2010
9. Barker N, Clevers H: Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 5:997-1014, 2006 (Pubitemid 44835127)
10. Yap TA, Olmos D, Molife LR, et al: Targeting the insulin-like growth factor signaling pathway: Figitumumab and other novel anticancer strategies. Expert Opin Investig Drugs 20:1293-1304, 2011
11. Yap TA, de Bono JS: Targeting the HGF/c-Met axis: State of play. Mol Cancer Ther 9:1077-1079, 2010
12. Yap TA, Garrett MD, Walton MI, et al: Targeting the PI3K-AKT-mTOR pathway: Progress, pitfalls, and promises. Curr Opin Pharmacol 8:393-412, 2008
13. Poulikakos PI, Solit DB: Resistance to MEK inhibitors: Should we co-target upstream? Sci Signal 4:pe16, 2011
14. Tolcher AW, Baird RD, Patnaik A, et al: A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. J Clin Oncol 29:195s, 2011 (suppl; abstr 3004)
15. Baselga J, Corté s J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
16. Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 379:633-640, 2012
17. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-1703, 2012
18. Carver BS, Chapinski C, Wongvipat J, et al: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575-586, 2011
19. Chandarlapaty S, Sawai A, Scaltriti M, et al: AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19:58-71, 2011
20. Wilson TR, Fridlyand J, Yan Y, et al: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505-509, 2012
21. Yap TA, Sandhu SK, Workman P, et al: Envisioning the future of early anticancer drug development. Nat Rev Cancer 10:514-523, 2010
22. Al-Lazikani B, Banerji U, Workman P: Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 30:679-692, 2012
23. Chappell WH, Steelman LS, Long JM, et al: Ras/ Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health. Oncotarget 2:135-164, 2011
24. Carracedo A, Pandolfi PP: The PTEN-PI3K pathway: Of feedbacks and cross-talks. Oncogene 27:5527-5541, 2008
25. Workman P: Challenges of PK/PD measurements in modern drug development. Eur J Cancer 38:2189-2193, 2002 (Pubitemid 35223253)
26. Workman P: How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 9:891-902, 2003 (Pubitemid 36367612)
27. Castellano E, Downward J: RAS interaction with PI3K: More than just another effector pathway. Genes Cancer 2:261-274, 2011
28. O'Reilly KE, Rojo F, She QB, et al: MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508, 2006 (Pubitemid 43259931)
29. Zhang WW, Cortes JE, Yao H, et al: Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 27:3642-3649, 2009
30. Yap TA, Zivi A, Omlin A, et al: The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 8:597-610, 2011
31. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
32. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
33. de Bono JS, Ashworth A: Translating cancer research into targeted therapeutics. Nature 467: 543-549, 2010
34. Yap TA, Gerlinger M, Futreal PA, et al: Intratumor heterogeneity: Seeing the wood for the trees. Sci Transl Med 4:127ps10, 2012
35. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892, 2012
36. Leary RJ, Sausen M, Kinde I, et al: Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4:162ra154, 2012
37. Perkins G, Yap TA, Pope L, et al: Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One 7:e47020, 2012
38. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
39. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003 (Pubitemid 36302244)
40. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
41. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
42. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
43. Yap TA, Workman P: Exploiting the cancer genome: Strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol 52:549-573, 2012
44. Solit DB, Garraway LA, Pratilas CA, et al: BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-362, 2006 (Pubitemid 43128863)
45. Wee S, Jagani Z, Xiang KX, et al: PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69:4286-4293, 2009
46. Kummar S, Chen HX, Wright J, et al: Utilizing targeted cancer therapeutic agents in combination: Novel approaches and urgent requirements. Nat Rev Drug Discov 9:843-856, 2010
47. Verweij J, Disis ML, Cannistra SA: Phase I studies of drug combinations. J Clin Oncol 28:4545-4546, 2010
48. US Food and Drug Administration: Guidance for industry: Codevelopment of two or more unmarketed investigational drugs for use in combination. http:// www.fda.gov/ForConsumers/ByAudience/ForPatient Advocates/ucm237264.htm
49. Kwak EL, Clark JW, Chabner B: Targeted agents: The rules of combination. Clin Cancer Res 13:5232-5237, 2007 (Pubitemid 47510344)
50. Hamberg P, Verweij J: Phase I drug combination trial design: Walking the tightrope. J Clin Oncol 27:4441-4443, 2009
51. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptorpositive advanced breast cancer. N Engl J Med 366:520-529, 2012
52. Ramalingam SS, Spigel DR, Chen D, et al: Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 29:4574-4580, 2011
53. Sequist LV, von Pawel J, Garmey EG, et al: Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29:3307-3315, 2011
54. UK Medicines Information: New drugs online. http://www.ukmi.nhs.uk/ applications/ndo/record-view-open.asp?newDrugID-5189
55. Spigel DR, Ervin TJ, Ramlau R, et al: Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29:477s, 2011 (suppl; abstr 7505)
56. Spigel DR, Edelman MJ, Mok T, et al: The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC). J Clin Oncol 30:508s, 2012 (suppl; abstr TPS7616)
57. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359: 2131-2139, 2002 (Pubitemid 34694019)
58. Cook T, DeMets DL: Review of draft FDA adaptive design guidance. J Biopharm Stat 20:1132-1142, 2010
59. Iyer G, Hanrahan AJ, Milowsky MI, et al: Genome sequencing identifies a basis for everolimus sensitivity. Science 338:221, 2012
60. Mathijssen RH, Loos WJ, Verweij J: Determining the best dose for the individual patient. J Clin Oncol 29:4345-4346, 2011
61. Yap TA, Yan L, Patnaik A, et al: First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29:4688-4695, 2011
62. Richards J, Lim AC, Hay CW, et al: Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: A rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 72:2176-2182, 2012
63. Ratain MJ, Sargent DJ: Optimising the design of phase II oncology trials: The importance of randomisation. Eur J Cancer 45:275-280, 2009
64. Polley MY: Practical modifications to the timeto-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities. Stat Med 30:2130-2143, 2011
65. Goodwin R, Giaccone G, Calvert H, et al: Targeted agents: How to select the winners in preclinical and early clinical studies? Eur J Cancer 48:170-178, 2011
66. Attard G, de Bono JS: Utilizing circulating tumor cells: Challenges and pitfalls. Curr Opin Genet Dev 21:50-58, 2011
67. Tunariu N, Kaye SB, Desouza NM: Functional imaging: What evidence is there for its utility in clinical trials of targeted therapies? Br J Cancer 106:619-628, 2012
68. Yap TA, Sarker D, Kaye SB, et al: Functional imaging: Clinical applications in molecular targeted therapy, in Husband J, Reznek RH (eds): Imaging in Oncology (ed 3). London, United Kingdom, Informa Healthcare, 2010, pp 1366-1383
69. Rodon J, Perez J, Kurzrock R: Combining targeted therapies: Practical issues to consider at the bench and bedside. Oncologist 15:37-50, 2010
70. Sato T, Stange DE, Ferrante M, et al: Longterm expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141:1762-1772, 2011
71. Das Thakur M, Salangsang F, Landman AS, et al: Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature [epub ahead of print on January 9, 2013]
72. Ma WW, Adjei AA: Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59:111-137, 2009